Methylenedioxydimethylamphetamine

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MDDM's dose as greater than 150mg orally and its duration as unknown. Findings on the effects of MDDM are very mixed. In two reports, with 150mg and 1,000mg both orally, no effects whatsoever occurred. In another report, 550mg orally resulted in very negative effects. Finally, two people who used 200mg orally found that it produced very pleasant effects for 20minutes, wore off, but then resurged to produce even stronger effects 4hours later. The higher-dose reports were communicated to Shulgin anonymously and he was uncertain whether the actual substance employed was indeed MDDM. More research seems necessary to characterize MDDM, but Shulgin expected that a "pretty hefty dose" would be required for it to produce effects.

Pharmacology

Pharmacodynamics

MDDM shows reduced potency as a monoamine releasing agent and reuptake inhibitor compared to MDA and MDMA. It was 11-fold less potent than MDMA and 4-fold less potent than MDA as a serotonin releasing agent (SRA). Moreover, whereas MDA and MDMA are serotonin–norepinephrine–dopamine releasing agents (SNDRAs), MDDM is a selective SRA along with ≥10-fold weaker dopamine and norepinephrine reuptake inhibition. The related drug MDTMA is completely inactive as a monoamine releasing agent, though it does still show very weak monoamine reuptake inhibition. Another related drug, dimethylamphetamine, is said to be a prodrug of methamphetamine and amphetamine, although it is much less potent and weaker than these drugs.

Chemistry

Impurity

MDDM is occasionally encountered as an impurity in MDMA which has been synthesized by methylation of MDA using methylating chemical reagents such as methyl iodide. An excess of reagent or a reaction temperature that is too high results in some double methylation of the amine nitrogen, yielding MDDM as well as MDMA. The presence of MDDM as an impurity can thus reveal which synthetic route was used to manufacture seized samples of MDMA.

Analogues

Analogues of MDDM include MDTMA (N,N,N-trimethyl-MDA) and dimethylone (βk-MDDM), among others.

Society and culture

Legal status

Canada

MDDM is a controlled substance in Canada.

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.

References

References

1. {{CitePiHKAL https://erowid.org/library/books_online/pihkal/pihkal105.shtml
2. (November 2025). ""New kid on the block"-MDDM as a new ingredient in Ecstasy tablets". J Forensic Sci.
3. (January 2016). "Binding Mode Selection Determines the Action of Ecstasy Homologs at Monoamine Transporters". Mol Pharmacol.
4. (9 October 2013). "Forensic Medicine: Fundamentals and Perspectives". Springer Science & Business Media.
5. (May 2002). "Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results". J Occup Environ Med.
6. (August 1987). "The metabolism of dimethylamphetamine in rat and man". Xenobiotica.
7. (September 2005). "LC-MS/MS in the elucidation of an isomer of the recreational drug methylenedioxy ethylamphetamine: methylenedioxy dimethylamphetamine". Journal of Separation Science.
8. (July 2007). "Postmortem distribution of 3,4-methylenedioxy-N,N-dimethyl-amphetamine (MDDM or MDDA) in a fatal MDMA overdose". International Journal of Legal Medicine.
9. (October 2010). "GC-MS studies on side chain regioisomers related to substituted methylenedioxyphenethylamines: MDEA, MDMMA, and MBDB". Journal of Chromatographic Science.
10. "Controlled Drugs and Substances Act".
11. "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design.